Mizuho Upgrades Relmada Therapeutics to Outperform, Raises Price Target to $10
Benzinga Newsdesk 11 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Mizuho analyst Uy Ear upgrades Relmada Therapeutics (NASDAQ:RLMD) from Neutral to Outperform and raises the price target from $1 to $10.
Mizuho analyst Uy Ear upgrades Relmada Therapeutics (NASDAQ:RLMD) from Neutral to Outperform and raises the price target from $1 to $10.